Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab + Docetaxel in Previously Treated NSCLC (CANOPY-2)
NCT03626545Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2019
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of canakinumab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Jan 2019; status: terminated.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03626545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626545.